Clinical trial
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic…
NCT00062816 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00062816 |
|---|---|
| Title | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | ISIS 14803, peginterferon alfa, ribavirin |
| Enrollment | 22 |
| Start date | Jun 1, 2003 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Jun 18, 2003 |
| Last update posted | Dec 5, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: